Trending/cancer drugs
Carfilzomib is not superior to Bortezomib in delaying multiple myeloma progression after initial treatment
ROCHESTER, Minn. ― Carfilzomib, a proteasome inhibitor used in combination with Lenalidomide, an immune modulating drug, is not superior to Bortezomib, Lenalidomide and Dexamethasone, in the initial treatment of multiple myeloma according…
July 27, 2015
January 8, 2015
March 21, 2013
Special Topics
Sign up
Mayo Clinic Connect
An online patient support community